These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26418254)

  • 1. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
    Hu S; Fu S; Xu X; Chen L; Xu J; Li B; Qu Y; Yu H; Lu S; Li W
    Cell Physiol Biochem; 2015; 37(3):1219-30. PubMed ID: 26418254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
    Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
    J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair.
    Capalbo G; Dittmann K; Weiss C; Reichert S; Hausmann E; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):226-34. PubMed ID: 20394854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
    Reichert S; Rödel C; Mirsch J; Harter PN; Tomicic MT; Mittelbronn M; Kaina B; Rödel F
    Radiother Oncol; 2011 Oct; 101(1):51-8. PubMed ID: 21852011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knocking Down Nucleolin Expression Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Influencing DNA-PKcs Activity.
    Xu JY; Lu S; Xu XY; Hu SL; Li B; Qi RX; Chen L; Chang JY
    Asian Pac J Cancer Prev; 2015; 16(8):3301-6. PubMed ID: 25921135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G₂/M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair.
    Dukaew N; Konishi T; Chairatvit K; Autsavapromporn N; Soonthornchareonnon N; Wongnoppavich A
    Oncol Res; 2020 Mar; 28(2):161-175. PubMed ID: 31727206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
    Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
    J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
    Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
    Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.
    Lai PC; Chen SH; Yang SH; Cheng CC; Chiu TH; Huang YT
    Pediatr Neonatol; 2012 Jun; 53(3):199-204. PubMed ID: 22770110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X; Su H
    Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
    Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.